These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15719581)

  • 21. [Argatroban: pharmacological properties and anaesthesiological aspects].
    Kleinschmidt S; Stephan B; Pindur G; Bauer C
    Anaesthesist; 2006 Apr; 55(4):443-50. PubMed ID: 16389543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Argatroban, a new treatment option for heparin-induced thrombocytopenia.
    Cleveland KW
    Crit Care Nurse; 2003 Dec; 23(6):61-6. PubMed ID: 14692173
    [No Abstract]   [Full Text] [Related]  

  • 23. [Heparin-induced thrombocytopenia].
    Koide M; Matsuo T
    Ryoikibetsu Shokogun Shirizu; 1998; (21 Pt 2):307-10. PubMed ID: 9833497
    [No Abstract]   [Full Text] [Related]  

  • 24. Anticoagulant therapy with MD805 of a hemodialysis patient with heparin-induced thrombocytopenia.
    Matsuo T; Yamada T; Yamanashi T; Ryo R
    Thromb Res; 1990 Jun; 58(6):663-6. PubMed ID: 2385832
    [No Abstract]   [Full Text] [Related]  

  • 25. Argatroban for Treatment of Heparin-Induced Thrombocytopenia and Thrombosis in a Patient with Multiple Myeloma Undergoing Hemodialysis.
    Giorgi-Pierfranceschi M; Mumoli N; Scarpioni R; Croci E; Dentali F
    J Am Geriatr Soc; 2016 Aug; 64(8):1748-50. PubMed ID: 27448437
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia.
    Bain J; Meyer A
    Am J Health Syst Pharm; 2015 Sep; 72(17 Suppl 2):S104-9. PubMed ID: 26272889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical evaluation of MD-805].
    Matsuo T
    Rinsho Byori; 1987 Sep; Spec No 73():150-60. PubMed ID: 3437530
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety and effectiveness outcomes of an inpatient collaborative drug therapy management service for direct thrombin inhibitors.
    Cooper T; White CL; Taber D; Uber WE; Kokko H; Mazur J
    Am J Health Syst Pharm; 2012 Nov; 69(22):1993-8. PubMed ID: 23135566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Argatroban.
    Kathiresan S; Shiomura J; Jang IK
    J Thromb Thrombolysis; 2002 Feb; 13(1):41-7. PubMed ID: 11994559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heparin-induced thrombocytopenia with aortoiliac thrombosis treated with argatroban.
    Alarcón Pérez L; Rodríguez Huerta AM; Duque González P
    Med Clin (Barc); 2017 Mar; 148(6):286-287. PubMed ID: 28131516
    [No Abstract]   [Full Text] [Related]  

  • 31. Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT)--bridging the River Coumarin.
    Warkentin TE
    Thromb Haemost; 2008 Jan; 99(1):2-3. PubMed ID: 18217128
    [No Abstract]   [Full Text] [Related]  

  • 32. Argatroban for treatment of heparin-induced thrombocytopenia.
    Med Lett Drugs Ther; 2001 Feb; 43(1097):11-2. PubMed ID: 11177224
    [No Abstract]   [Full Text] [Related]  

  • 33. Pulmonary embolism and heparin-induced thrombocytopenia successfully treated with tissue plasminogen activator and argatroban.
    Hourmouzis Z; Bhalla MC; Frey JA; Jwayyed S
    Am J Emerg Med; 2015 May; 33(5):739.e5-6. PubMed ID: 25497698
    [No Abstract]   [Full Text] [Related]  

  • 34. [Experimental and clinical results with the thrombin inhibitor Argatroban].
    Breddin HK
    Hamostaseologie; 2002 Aug; 22(3):55-9. PubMed ID: 12215762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients.
    Gray A; Wallis DE; Hursting MJ; Katz E; Lewis BE
    Clin Appl Thromb Hemost; 2007 Oct; 13(4):353-61. PubMed ID: 17911186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A synopsis of the clinical uses of argatroban.
    Moledina M; Chakir M; Gandhi PJ
    J Thromb Thrombolysis; 2001 Oct; 12(2):141-9. PubMed ID: 11729365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
    Jeske WP; Walenga JM
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1171-80. PubMed ID: 12211410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
    Lewis BE; Hursting MJ
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):57-68. PubMed ID: 17187457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in parenteral direct thrombin inhibitor use in pediatric patients: analysis of a large administrative database.
    Moffett BS; Teruya J
    Arch Pathol Lab Med; 2014 Sep; 138(9):1229-32. PubMed ID: 25171706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unexpectedly Low Fibrinogen.
    Zhang L; Fan Q; Zhang Z
    Clin Chem; 2020 Sep; 66(9):1248-1249. PubMed ID: 32870988
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.